Add to ORKGThe discovery of endothelin created a lot of enthusiasm and paved new therapeutic avenues for the treatment of arterial hypertension. Endothelin plays a significant role in blood pressure regulation through pronounced vasoconstriction and modulation of sodium and water reabsorption in the kidneys. Endothelin receptor antagonists have been tested in many clinical trials in patients with arterial hypertension, heart failure, pulmonary arterial hypertension, systemic sclerosis, chronic kidney disease, and diabetic nephropathy. However, the results were usually disappointing, except in pulmonary hypertension and scleroderma digital ulcers. The future of ERAs for the treatment of arterial hypertension and chronic kidney disease does not seem bri...
Since its discovery in 1988 the powerful vasoconstrictor endothelin-1 (ET-1) has been widely implic...
The burden of chronic kidney disease is increasing worldwide, largely due to the increasing global p...
Hypertension is the most common risk factor worldwide forcardiovascular morbidity and mortality.1,2 ...
To review the most recent data on the development of endothelin receptor antagonists (ERAs) for the ...
The discovery in 1988 of endothelin, the most potent human endogenous vasoconstrictor, has opened th...
AbstractDiabetes and arterial hypertension continue to be the main causes of chronic renal failure i...
AbstractAimsThe demonstration that endothelin production is upregulated in pulmonary artery hyperten...
The incidence and prevalence of chronic kidney disease (CKD), with diabetes and hypertension account...
The endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for the...
The endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for the...
AbstractEndothelin receptor antagonists (ETRAs) are approved for the treatment of pulmonary hyperten...
AbstractIn the early 1990s, within three years of cloning of endothelin receptors, orally active end...
Abstract: Endothelin (ET) is an important modulator of renal function through its binding to ETA and...
Pulmonary arterial hypertension (PAH) is a rare but debilitating disease, which if left untreated ra...
The burden of chronic kidney disease is increasing worldwide, largely due to the increasing global p...
Since its discovery in 1988 the powerful vasoconstrictor endothelin-1 (ET-1) has been widely implic...
The burden of chronic kidney disease is increasing worldwide, largely due to the increasing global p...
Hypertension is the most common risk factor worldwide forcardiovascular morbidity and mortality.1,2 ...
To review the most recent data on the development of endothelin receptor antagonists (ERAs) for the ...
The discovery in 1988 of endothelin, the most potent human endogenous vasoconstrictor, has opened th...
AbstractDiabetes and arterial hypertension continue to be the main causes of chronic renal failure i...
AbstractAimsThe demonstration that endothelin production is upregulated in pulmonary artery hyperten...
The incidence and prevalence of chronic kidney disease (CKD), with diabetes and hypertension account...
The endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for the...
The endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for the...
AbstractEndothelin receptor antagonists (ETRAs) are approved for the treatment of pulmonary hyperten...
AbstractIn the early 1990s, within three years of cloning of endothelin receptors, orally active end...
Abstract: Endothelin (ET) is an important modulator of renal function through its binding to ETA and...
Pulmonary arterial hypertension (PAH) is a rare but debilitating disease, which if left untreated ra...
The burden of chronic kidney disease is increasing worldwide, largely due to the increasing global p...
Since its discovery in 1988 the powerful vasoconstrictor endothelin-1 (ET-1) has been widely implic...
The burden of chronic kidney disease is increasing worldwide, largely due to the increasing global p...
Hypertension is the most common risk factor worldwide forcardiovascular morbidity and mortality.1,2 ...